AzTrials
AzTrials

Advanced Solid TumorsPhase 1/2NCT00842335

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

A Phase 1/2 study testing JI-101 in people with Advanced Solid Tumors, run by Jubilant Innovation Ltd. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumors
What is being tested?
JI-101
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteUnited States
Study dates
Feb 2009to Jan 2012
Phase
Phase 1/2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Be 18 years of age or greater at the time of consent.
  • Have solid tumors for which no approved therapy or standard of care is available or have solid tumors and have failed standard-of-care therapy.
  • Have life expectancy of greater than 3 months.
  • Have Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
  • Have organ and marrow function as defined below:
  • absolute neutrophil count ≥ 1.5 x 10^9 cells/L
Show all 18Show fewer
  • hemoglobin ≥ 9.0 g/dL
  • platelets ≥ 75 x 10^9 cells/L
  • total bilirubin ≤ 1.5 x upper limit of normal (ULN)
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 x ULN (≤ 5 x ULN for liver metastases)
  • serum creatinine < 1.5 x ULN
  • < 500 mg urinary protein/24 hours or dipstick < 2+
  • No evidence of preexisting uncontrolled hypertension as documented by two baseline blood pressure readings taken at least 1 hour apart (the baseline systolic blood pressure readings must be <140 mm Hg, and the baseline diastolic blood pressure readings must be <90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible)
  • Have no clinically significant disease that poses a risk to the patient and/or would interfere with study evaluations or procedures.
  • Have within normal range cardiac function as measured by twelve-lead electrocardiogram at Screening.
  • Be clinically euthyroid.
  • If female, must be postmenopausal (at least 1 year from last menses), or surgically sterile, or if a female patient of childbearing potential they must agree to use acceptable methods of birth control, which include local double-barrier contraceptive methods, such as cervical diaphragm plus spermicide, female condom plus spermicide, or a non-hormonal intrauterine device (IUD) plus spermicide, or systemic contraceptive methods, such as oral, injectable, transdermal or implantable hormonal contraceptives (including hormone-containing IUDs) during the study period, and for 30 days after the last dose of study drug. Female patients of childbearing potential must have a negative serum pregnancy test within the 3 days before the first study drug administration. Male patients must be surgically sterile or also agree to use acceptable methods of birth control with their female partners, and this may include use of a male condom plus spermicide. If the subject is practicing abstinence at the time of Screening, he/she must agree to use a double-barrier contraceptive method if he/she becomes sexually active.
  • Be able to understand and the willingness to sign a written informed consent document.

Who cannot join

  • Be pregnant or breastfeeding.
  • Have a known history of human immunodeficiency virus (HIV) infection because the effect of JI-101 on immunosuppression and drug interactions with anti-retroviral medications is unknown.
  • Have participated in an investigational drug/device/biologic study within 30 days (or within 5 half-lives of the treatment, whichever is longer) before Visit 1 or who are currently participating in another investigational drug/device/biologic study. Participation in non-interventional or observational studies is allowed.
  • Have a history of cardiac abnormalities including: abnormal and clinically relevant ECGs; frequent palpitations or syncopal episodes; heart failure; hypokalemia; stroke; family history of Long QT Syndrome; acute myocardial infarction or ventricular tachyarrhythmia within the previous 12 months.
  • Have used concomitant medications that prolong the QT/QTc interval within 14 days prior to Day 1.
  • Have a history of significant retinopathy or any progressive eye disease that could lead to severe loss of visual acuity or visual field loss during the study period.
Show all 15Show fewer
  • Have had therapeutic reanticoagulation with heparin or heparin analogs (low molecular weight heparins) or warfarin within the past 4 weeks. Low dose warfarin (1 to 2 mg/day) is allowed for prophylaxis treatment.
  • Have had major surgery, radiotherapy, chemotherapy, or cytokine therapy within 4 weeks of treatment initiation. Patients must have recovered to baseline or grade 1 from any clinically significant adverse event experienced during those prior therapies.
  • Have gastrointestinal abnormalities including inability to take oral medications, malabsorption syndromes or other clinically significant GI abnormalities that may impair the absorption of JI-101 in the opinion of the Investigator.
  • Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would pose a risk to patient safety or that would limit compliance with study requirements.
  • Have any condition that, in the opinion of the Investigator, would interfere with a patient's ability to perform the required activities of the study or would subject the patient to undue risk.
  • Patients with proteinuria (patients with >2+ protein on urine dipstick) at baseline should undergo a 24-hour urine collection. Results must demonstrate <500 mg of protein in 24 hours to allow participation in the study)
  • Patients with any of the following contraindications to FDG-PET can participate in the study if all of the inclusion criteria and none of the exclusion criteria are met, but these patients are excluded from FDG PET assessments:
  • o Inability to remain lying down in PET scanner (for PET portion of the study).
  • Absence of at least one metastatic lesion greater than or equal to 2 cm on pre-dose CT (computed tomography) scan or other radiographic imaging as defined by response evaluation criteria in solid tumors (RECIST) criteria.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Premiere Oncology of Arizona

    Scottsdale, Arizona, 85258

Other trials in United States

About this study

Official title: A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may provide benefit to patients with solid tumors that have failed standard therapeutic regimens.

Read the detailed description

JI-101 is a compound being developed for the treatment of patients with solid tumors; specifically patients for which no approved therapy or standard of care is available or have solid tumors and have failed standard of care therapy. JI-101 is an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and EphB4 receptor, each of which plays an important role in driving vascularization (angiogenesis and vasculogenesis) during normal development and tumorigenesis. JI-101 inhibits the growth of new blood vessels, which in turn, may slow or prevent the growth of tumors. The purpose of this open label study is to treat patients with advanced solid tumors, with increasing doses of JI-101, thereby providing information about the maximum tolerated dose (MTD). The study will also examine safety, tolerability, pharmacokinetics, pharmacodynamics, and may evaluate the effects of the drug on tumor metabolism. During this dose-escalation study, at least two patients will be dosed at each dose level (cohort). The patients must complete 21 days of dosing and safety results will be reviewed prior to any patients being assigned the next higher dose level. A continuous reassessment method will be utilized to escalate JI-101 doses between cohorts. Doses will be increased, with an anticipated high dose of 800mg per day. If the MTD is not reached, an optimal biologic dose (OBD) will be determined based on the highest doses that are tolerable with acceptable efficacy. The cohort at MTD or OBD will be expanded to include up to 30 patients with solid tumors to further explore the safety and tolerability of orally-administered JI-101.

Being tested
JI-101
Keywords
solid tumors, angiogenesis inhibitor, dose escalation, maximum tolerated dose, JI-101

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • JI-101Drug

    JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication

Study groups in NCT00842335
Study groupRoleWhat they receive
JI-101ExperimentalNot described
Receives: Drug: JI-101

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose (MTD) of JI-101

    The primary objective of this study was to determine the maximum tolerated dose (MTD) of JI-101 when administered orally in patients with advanced solid tumors.

    The MTD was established based on safety data from Cycle 1. Patients who completed 21 days of treatment in Cycle 1 were considered to have completed the study for the determination of MTD.

    Patients were eligible to continue treatment with JI-101 until they experienced disease progression or unacceptable treatment-related toxicity. Unacceptable treatment-related toxicity was defined as a clinically significant AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, and that was attributed to JI 101.

    Measured: 28 days (1 cycle)

Secondary outcomes (3)

  1. Number of Participants Reaching Maximum Tolerated Dose

    Number of participants withdrawn from study due to adverse events

    Measured: Up to 112 days (up to four 28-day cycles) or longer if the patient is benefiting from treatment

  2. Overall Clinical Response by Cycle

    Stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.

    Progressive disease: At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions

    Measured: Up to 112 days ( four 28-day cycles)

  3. Days to Progression

    Progression: At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions

    Measured: Up to 112 days (four 28-day cycles) or longer if the patient is benefiting from treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Feb 2009 (estimated)
  2. Study startFeb 2009
  3. Primary completionJul 2010
  4. Study completionJan 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00842335
Sponsor's protocol ID
JI-101-001
Status last verified
Jun 2013
First submitted
11 Feb 2009
Last updated
24 Jun 2013
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing JI-101 in people with Advanced Solid Tumors, run by Jubilant Innovation Ltd. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 Jun 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (MTD) of JI-101 (time frame: 28 days (1 cycle)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00842335.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2013.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in